National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Brain and Central Nervous System Tumors

Primary brain and central nervous system (CNS) tumors are formed by the abnormal growth of cells and may begin in different parts of the brain or spinal cord. They can be benign (not contain cancer cells) or malignant (contain cancer cells) and can occur in both adults and children.

Primary brain and CNS cancer is rare. The chance that a person born today will develop a cancer of the brain or spinal cord in his or her lifetime is less than 1 percent.

Sometimes cancers that start elsewhere in the body spread to one or more parts of the brain. These are called metastatic brain tumors or brain metastases. Metastatic brain tumors are more common than primary brain tumors.

It is estimated that 23,130* people in the United States will be diagnosed with primary brain and other CNS cancers in 2013.

Treatment options for brain and central nervous system tumors vary depending on the type of cancer, stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013

Brain Cancer Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with brain and central nervous system cancers. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Brain Tumor
Phase II
A Phase II Study of TRC105 in Patients With Recurrent Glioblastoma (GBM)
NCI-13-C-0048, NCT01757652

Principal Investigator:Referral Contact:
Joohee SulTracy Cropper
301-594-9349301-402-6298
Toll free: 866-251-9686
tcropper@mail.nih.gov
A Phase II Randomized Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
NCI-12-C-0136, NCT01553149

Principal Investigator:Referral Contact:
Katherine E. WarrenLinda Ellison
301-496-4256301-496-8009
ellisonl@mail.nih.gov
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
NCI-09-C-0222, NCT00995007

Principal Investigator:Referral Contact:
Katharine McNeillTracy Cropper
301-443-3441301-402-6298
Toll free: 866-251-9686
tcropper@mail.nih.gov
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas
NCI-06-C-0112, NCT00302159

Principal Investigator:Referral Contact:
Kevin A. CamphausenSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov
Phase I/II
PBTC-033 A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)
NCI-12-C-0213, NCT01514201

Principal Investigator:Referral Contact:
Katherine E. WarrenLinda Ellison
301-496-4256301-496-8009
ellisonl@mail.nih.gov
A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma
NCI-12-C-0004, NCT01026493

Principal Investigator:Referral Contact:
Teri KreislTracy Cropper
301-402-3423301-402-6298
Toll free: 866-251-9686
tcropper@mail.nih.gov
A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII
NCI-11-C-0266, NCT01454596

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
Phase I Trial of AZD7451, a Tropomyosin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)
NCI-12-C-0005, NCT01468324

Principal Investigator:Referral Contact:
Katharine McNeillTracy Cropper
301-443-3441301-402-6298
Toll free: 866-251-9686
tcropper@mail.nih.gov
A Phase I Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM)
NCI-11-C-0192, NCT01386463

Principal Investigator:Referral Contact:
Joohee SulTracy Cropper
301-594-9349301-402-6298
Toll free: 866-251-9686
tcropper@mail.nih.gov
Phase I and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
NCI-11-C-0191, NCT01386450

Principal Investigator:Referral Contact:
Katherine E. WarrenLinda Ellison
301-496-4256301-496-8009
ellisonl@mail.nih.gov
A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas
NCI-10-C-0219, NCT01226940

Principal Investigator:Referral Contact:
Katherine E. WarrenLinda Ellison
301-496-4256301-496-8009
ellisonl@mail.nih.gov
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma
NINDS-09-N-0117, NCT00880061

Principal Investigator:Referral Contact:
Russell R. LonserLinda Ellison
301-496-5728301-496-8009
ellisonl@mail.nih.gov
No Phase
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
NCI-06-C-0219, NCT00401037

Principal Investigator:Referral Contact:
Katherine E. WarrenLinda Ellison
301-496-4256301-496-8009
ellisonl@mail.nih.gov
A Comparative Study of Pediatric CNS Tumor Activity as Assessed by 18F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI)
NCI-03-C-0278, NCT00070512

Principal Investigator:Referral Contact:
Katherine E. WarrenLinda Ellison
301-496-4256301-496-8009
ellisonl@mail.nih.gov
Evaluation of the Natural History of Patients With Tumors of the Central Nervous System
NCI-01-C-0070, NCT00458640

Principal Investigator:Referral Contact:
Teri KreislTracy Cropper
301-402-3423301-402-6298
Toll free: 866-251-9686
tcropper@mail.nih.gov


  
Trial and Protocol Number
Breast Cancer
Phase II
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
NCI-12-C-0087, NCT01480583

Principal Investigator:Referral Contact:
Susan BatesChristine Bryla
301-402-5958301-451-7868
brylacm@mail.nih.gov


  
Trial and Protocol Number
Lymphoma
Phase II
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy
NCI-06-C-0051, NCT00267865

Principal Investigator:Referral Contact:
Robert YarchoanKaren Aleman
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
alemank@mail.nih.gov


  
Trial and Protocol Number
Neurofibroma/Neurofibromatosis
Phase I
A Phase II Study of Everolimus (RAD001) for Children With Neurofibromatosis Type-1 and Chemotherapy-Refractory Radiographic Progressive Low-Grade Gliomas
NCI-12-C-0058, NCT00901849

Principal Investigator:Referral Contact:
Katherine E. WarrenLinda Ellison
301-496-4256301-496-8009
ellisonl@mail.nih.gov


  
Trial and Protocol Number
Pediatric Cancers
Phase I
Phase I Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
NCI-11-C-0053, NCT01141244

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
NCI-11-C-0047, NCT01259479

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
NCI-10-C-0178, NCT01182896

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)



  
Trial and Protocol Number
Solid Tumor
Phase II
Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
NCI-12-C-0199, NCT01679743

Principal Investigator:Referral Contact:
Susan BatesChristine Bryla
301-402-5958301-451-7868
brylacm@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov